Automated Medical Device quickly processes bone marrow.August 18, 2009 -
Able to processes bone marrow within 15 minutes, Res-Q(TM) 60 BMC System optimizes rate of stem cell recovery. Functionally closed system features 60 mL chamber and is specifically used for concentration of bone marrow-derived stem cells at point of care. Packaged for sterile field, system is and designed to provide high-quality cell concentrates from bone marrow aspirates for orthopedic regenerative medicine market.
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Original Press release
ThermoGenesis Corp.
11431 Sunrise Gold Cir., Suite A
Rancho Cordova, CA, 95742
USA
ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector
RANCHO CORDOVA, Calif., Aug. 6 -- ThermoGenesis Corp. (NASDAQ:KOOL), a leading supplier of innovative products for processing and storing adult stem cells, announced today the introduction of the Res-Q(TM) 60 BMC ("Res-Q") System, an automated cell processing medical device for the concentration of bone marrow-derived stem cells at the point of care.
The Res-Q System processes bone marrow in minutes and delivers a high rate of stem cell recovery. The Res-Q System follows the late 2008 launch of the MXP(TM) MarrowXpress(TM) ("MXP") System, a laboratory device also used to collect stem cells from bone marrow.
The Company plans to initially target the orthopedic regenerative medicine market through its orthopedic distribution partner Celling Technologies ("Celling"), a subsidiary of SpineSmith, LLC. Celling is a leading distributor of orthopedic products based in Texas and also serves as a distributor of the MXP System. In a separate press release today, ThermoGenesis and Celling announced an expanded collaboration between the two firms. Separately, the Company plans to expand Res-Q's applications into the cardiovascular and other non-orthopedic regenerative medicine markets.
"We are excited to add a new member to our stem cell processing product family to help us access the growing regenerative medicine market in a meaningful way. We believe our Res-Q System has considerable advantages over competing products and should help surgeons realize the true value of autologous cellular therapy," said J. Melville Engle, Chief Executive Officer of ThermoGenesis.
"We are delighted to be participating in the launch of the Res-Q System with ThermoGenesis," said Kevin Dunworth, Chief Executive Officer of SpineSmith, LLC. "The device represents a high level of innovative technology and we look forward to building upon our early success with the MXP," he added.
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:
-- The BioArchive System, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.
-- AXP AutoXpress(TM) Platform ("AXP"), a proprietary family of automated devices that includes the AXP and the MXP(TM) MarrowXpress and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China and Russia/CIS, where ThermoGenesis markets through independent distributors. The MXP is used for isolating stem cells from bone marrow.
-- The Res-Q(TM) 60 BMC ("Res-Q"), a point of care system that is designed for bone marrow stem cell processing. This product was launched in July 2009.
-- The CryoSeal FS System, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.
ThermoGenesis Corp.
Web site: http://www.thermogenesis.com/
|
|
|
|
|
|
|
| 
